A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer.
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Evaluate response rate
Approximately every 8 weeks with imaging
No
Matthew Fury, MD,PhD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
08-039
NCT00661427
November 2007
August 2012
Name | Location |
---|---|
Memorial Sloan Kettering Cancer Center | New York, New York 10021 |
Washington University School of Medicine | Saint Louis, Missouri 63110 |
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
Pennsylvania Hospital | Philadelphia, Pennsylvania 19107 |
University of Nebraska Medical Center | Omaha, Nebraska 68198-3330 |
University of Tennessee Cancer Institute | Memphis, Tennessee 38103 |
City of Hope National Medical Center | Los Angeles, California 91010 |
Huntsman Cancer Institue | Salt Lake City, Utah 84112 |
Memorial Sloan-Kettering Cancer Center at Basking Ridge | Basking Ridge, New Jersey 07920 |
Memorial Sloan-Kettering Cancer Center at Commack | Commack, New York 11725 |
Memorial Sloan-Kettering at Mercy Medical Center | Rockville Centre, New York |
Memoral Sloan Kettering Cancer Center@Phelps | Sleepy Hollow, New York |
NorthShore University health system | Evanston, Illinois 60201 |
H. Lee Moffit Cancer Center and Research Institute | Tampa, Florida 33612 |
Fox Chase Virtua Health Cancer Program | Philadelphia, Pennsylvania 08060 |
University of Pennsylvania - Abramson Cancer Center | Philadelphia, Pennsylvania 19104-4283 |
Abramson Cancer Center University of Pennsylvania | Philadelphia, Pennsylvania 19104 |